Ischemic Attack, Transient
Brief reversible episodes of focal, nonconvulsive ischemic dysfunction of the brain having a duration of less than 24 hours, and usually less than one hour, caused by transient thrombotic or embolic blood vessel occlusion or stenosis. Events may be classified by arterial distribution, temporal pattern, or etiology (e.g., embolic vs. thrombotic). (From Adams et al., Principles of Neurology, 6th ed, pp814-6)
Drugs by status
Approved for this indication (1)
Phase 4 trials (17)
Phase 3 trials (9)
Phase 2 trials (7)
Phase 1 trials (1)
Organizations
Organization Involved with Phase 4 Indications (4)
Organization Involved with Phase 3 Indications (30)
- Bristol-Myers Squibb
- AstraZeneca
- Merck
- Sanofi
- Codman & Shurtleff
- The EMMES Corporation
- Katholieke Universiteit Leuven
- University of Edinburgh
- University of Limerick
- University of South Florida
- University of Athens
- Capital Medical University
- Peking University
- University of Calgary
- University of California, San Francisco
- Medical University of South Carolina
- Jinan University
- University of Oxford
- Government of China
- Mater Adult Hospital
- University of Paris
- National Health and Medical Research Council, Australia
- Canadian Institutes of Health Research (CIHR)
- Health Research Board, Ireland
- Irish Heart Foundation
- Universitat de Lleida
- Neurological Emergencies Treatment Trials Network
- Canadian Stroke Consortium (CSC)
- National University of Ireland
- The University of Texas, Dallas
Organization Involved with Phase 2 Indications (17)
- AdvanceCor GmbH
- Bayer
- GlaxoSmithKline
- National Institute of Neurological Disorders and Stroke (NINDS)
- University of London
- Dong-A University
- Inje University
- Korea University
- Seoul National University
- University of Turku
- University of Ulsan
- Janssen Pharmaceutica NV
- Ewha Womans University
- Kyungpook University
- Hallym University
- Technical University of Munich
- Orion Corporation
Organization Involved with Phase 1 Indications (3)
Organization Involved with Other Experimental Indications (9)